{
"id":"mk19_b_rm_s14",
"subspecialtyId":"rm",
"title":"Systemic Vasculitis",
"jsonContent":{
"type":"section",
"id":"mk19_b_rm_s14",
"title":{
"__html":"Systemic Vasculitis"
},
"titleNode":{
"type":"section-title",
"hlId":"995a84",
"children":[
"Systemic Vasculitis"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s14_1",
"title":{
"__html":"Overview"
},
"titleNode":{
"type":"section-title",
"hlId":"3b8782",
"children":[
"Overview"
]
},
"children":[
{
"type":"p",
"hlId":"d779bb",
"children":[
"Vasculitis is inflammation of blood vessels, including capillaries, arteries, and/or veins. Clinical manifestations result from tissue ischemia in the affected areas. Vasculitis can be primary, secondary to another underlying autoimmune disease, or triggered by other causes ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t38",
"wrapId":"1",
"children":[
"Table 38"
]
}
]
},
")"
]
},
". Vasculitis mimics must be considered in the differential diagnosis ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t39",
"wrapId":"1",
"children":[
"Table 39"
]
}
]
},
")"
]
},
". Primary autoimmune vasculitis disorders are discussed in this section."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_rm_t38",
"mk19_b_rm_t39"
]
},
{
"type":"p",
"hlId":"e0171d",
"children":[
"Vasculitis is not one disease, but many. These conditions are typically grouped into distinct categories according to clinical presentation and pathophysiology. A well-established classification scheme focuses on size of involved vessels. Vessel size can provide insight into processes and presentations, but conditions and vessel sizes may overlap."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_2",
"title":{
"__html":"Large-Vessel Vasculitis"
},
"titleNode":{
"type":"section-title",
"hlId":"04ff2b",
"children":[
"Large-Vessel Vasculitis"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s14_2_1",
"title":{
"__html":"Giant Cell Arteritis"
},
"titleNode":{
"type":"section-title",
"hlId":"509841",
"children":[
"Giant Cell Arteritis"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s14_2_1_1",
"title":{
"__html":"Epidemiology and Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"c25aa6",
"children":[
"Epidemiology and Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"415c98",
"children":[
"Giant cell arteritis (GCA; also called temporal arteritis) usually affects patients older than 50 years (peak incidence, 70-80 years). GCA is more common in White persons (incidence in Europe, 10-20/100,000). The female-to-male ratio is about 3:1."
]
},
{
"type":"p",
"hlId":"e3a494",
"children":[
"Histologically, GCA is characterized by granulomatous inflammation of large- and medium-sized arteries, with infiltration of CD4-positive lymphocytes, macrophages, and multinucleated giant cells. Inflammatory disruption of the internal elastic lamina is common. Involved vessels include the aorta; its major branches off the arch; and secondary branch vessels, including the external carotid, subclavian, axillary, temporal, ophthalmic, ciliary, occipital, and vertebral arteries. The vessel involved dictates the clinical symptoms."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_2_1_2",
"title":{
"__html":"Clinical Manifestations and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c6f6f6",
"children":[
"Clinical Manifestations and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"481428",
"children":[
"Common GCA symptoms include headache (typically temporal but occasionally more diffuse), constitutional symptoms, concomitant polymyalgia rheumatica (PMR), and scalp tenderness over the temporal artery. Symptoms can be unilateral or bilateral. Jaw aching and fatigue with chewing indicate ischemia (claudication) of the muscles of mastication. The most feared complication of GCA is ischemic optic neuropathy due to occlusion of the posterior ciliary or occasionally the ophthalmic artery, which can cause irreversible blindness. Early recognition and treatment of any visual change (e.g., reversible diplopia or visual defect) are critical. Intracranial ischemic strokes are rare."
]
},
{
"type":"p",
"hlId":"b287ea",
"children":[
"Extracranial disease involving great vessels in the chest and arms occurs in up to 50% of patients but is usually subclinical; it only sometimes results in upper extremity claudication. Severe but uncommon complications include aortic aneurysm and dissection. Up to 50% of patients with GCA have PMR, which may occur before, concurrent with, or after diagnosis of GCA (see ",
{
"type":"cross-reference",
"target":"mk19_b_rm_s14_2_2",
"children":[
"Polymyalgia Rheumatica"
]
},
")."
]
},
{
"type":"p",
"hlId":"f844e9",
"children":[
"Physical examination may reveal scalp or temporal artery tenderness and induration, reduced peripheral pulses, and bruits. Laboratory studies almost always show elevated erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP). Rarely, however, the inflammatory markers may be normal. Nonspecific evidence of inflammation may include anemia, elevated serum ferritin level, and thrombocytosis. Serologic testing reveals no specific autoantibodies (although low-level antinuclear antibody levels and rheumatoid factor are common in older patients)."
]
},
{
"type":"p",
"hlId":"a2f54d",
"children":[
"GCA is suspected on the basis of clinical presentation and should be confirmed, when possible, by temporal artery biopsy and/or imaging of the great vessels. New or atypical headache, jaw claudication, or visual changes in a patient older than 50 years, especially with concurrent PMR, should raise suspicion. Temporal artery biopsy is diagnostic, but false-negative results are common because of skip lesions; adequate biopsy sampling (>1-cm length of temporal artery) is crucial; although bilateral temporal artery biopsy can slightly increase the yield, unilateral biopsy is recommended. Temporal artery biopsy findings remain abnormal for up to 4 weeks after initiation of glucocorticoids. Given the risk for blindness, treatment should therefore be initiated first and biopsy performed within 2 weeks. If the pretest likelihood of disease is high, treatment may be continued even in the presence of a negative biopsy result."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_2_1_3",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"c056b7",
"children":[
"Suspected GCA should be treated immediately to prevent visual loss. Beginning high-dose prednisone (1 mg/kg/d, up to 80 mg) is recommended. Intravenous pulse methylprednisolone for 3 days is recommended for acute visual loss; however, data on this approach are limited, and established blindness is usually irreversible. Prednisone plus the interleukin-6 inhibitor tocilizumab is conditionally recommended as initial therapy because the combination is superior to prednisone alone and typically permits faster glucocorticoid taper. Symptoms and inflammatory markers usually respond rapidly to treatment; lack of response should prompt reconsideration of the diagnosis. High-dose prednisone is maintained for 2 to 4 weeks. Once symptoms resolve and inflammatory markers normalize, prednisone is tapered as tolerated, with a goal of reaching 20 mg/d within 2 to 3 months, at which point tapering is slowed. Glucocorticoids should be discontinued, when possible, within 6 months, but longer treatment may be warranted as dictated by disease activity. Patients should be monitored for symptom recurrence. ESR and/or CRP should be monitored monthly but should not be the sole indication for adjusting glucocorticoid dose. Mild flares can be managed with modest increases of prednisone and slower tapering. The addition of low-dose methotrexate may facilitate glucocorticoid tapering and may be considered in patients with significant glucocorticoid contraindications, although data are limited. At treatment initiation, all patients should undergo bone densitometry to stratify risk for glucocorticoid-induced osteoporosis and receive prophylaxis."
]
},
{
"type":"p",
"hlId":"116dad",
"children":[
"GCA is self-limited (2-6 years) in some patients but may be chronic in others. It also may recur. Appropriate and timely treatment can reduce risk for blindness."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_2_2",
"title":{
"__html":"Polymyalgia Rheumatica"
},
"titleNode":{
"type":"section-title",
"hlId":"3c34de",
"children":[
"Polymyalgia Rheumatica"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s14_2_2_1",
"title":{
"__html":"Epidemiology and Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"c25aa6",
"children":[
"Epidemiology and Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"fc7e33",
"children":[
"Although not a vasculitis, PMR is an inflammatory disorder that frequently (up to 50% of cases) accompanies GCA. PMR and GCA likely reflect the clinical spectrum of a single disease process, although PMR occurs 3 to 10 times more frequently. Patients presenting with PMR should be asked about arteritis symptoms because 10% to 20% have concomitant GCA."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_2_2_2",
"title":{
"__html":"Clinical Manifestations and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c6f6f6",
"children":[
"Clinical Manifestations and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"d7c504",
"children":[
"The classic picture of PMR is pain and stiffness of the shoulder girdle and hip girdle. Symptoms may affect some or all of these areas; symmetric presentation is classic. Pain and stiffness are most pronounced in the morning. Peripheral arthritis, generally mild and affecting the knees and wrists, may occur. Synovitis in the hands and feet is uncommon. Constitutional symptoms and laboratory findings resemble those of GCA, although normal inflammatory markers are more common in PMR than GCA. PMR is diagnosed clinically. Temporal artery biopsy should be performed only if GCA is suspected."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_2_2_3",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"3eda1f",
"children":[
"Unlike GCA, PMR responds dramatically to moderate-dose prednisone (12.5-20 mg/d); lack of a rapid response should prompt consideration of alternate diagnoses. Prednisone taper is initiated 4 weeks after symptoms resolve and requires months to years. Monitoring of recurrence is managed similarly to the approach used for GCA. For relapses, guidelines for the management of PMR (developed by the American College of Rheumatology and the European League Against Rheumatism) recommend increasing the prednisone dose to the last pre-relapse dose at which the patient was doing well, followed by a gradual reduction within 4 to 8 weeks to the relapse dose. Methotrexate can be used in select cases as a weak glucocorticoid-sparing agent."
]
},
{
"type":"p",
"hlId":"6f9644",
"children":[
"Prognosis is good, although periodic recurrences are common. If PMR treatment is initiated properly, patients whose PMR is not accompanied by GCA rarely progress to GCA. Several studies suggest the benefit of tocilizumab for treating PMR in the absence of GCA, but the agent is not approved for this purpose."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_2_3",
"title":{
"__html":"Takayasu Arteritis"
},
"titleNode":{
"type":"section-title",
"hlId":"ca3e31",
"children":[
"Takayasu Arteritis"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s14_2_3_1",
"title":{
"__html":"Epidemiology and Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"c25aa6",
"children":[
"Epidemiology and Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"cb076d",
"children":[
"Takayasu arteritis (TA) causes inflammation of the large vessels, most commonly the aorta, followed by the subclavian, common carotid, and renal arteries; the pulmonary arteries may also be involved. TA is rare, with a prevalence of 40 per million in Japan and up to 8 per million elsewhere. Although vascular involvement and clinical features overlap somewhat with GCA, TA predominantly affects younger women. Arterial lesions are often stenotic (“pulseless disease”), and one third are aneurysmal. Histopathology is similar to that of GCA."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_2_3_2",
"title":{
"__html":"Clinical Manifestations and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c6f6f6",
"children":[
"Clinical Manifestations and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"53c960",
"children":[
"TA manifestations include new-onset hypertension, limb claudication, postprandial abdominal pain due to mesenteric ischemia, reduced pulses, arterial bruits, and blood pressure discrepancies between the arms. Heart failure related to aortic insufficiency or coronary artery disease may occur. Neurologic manifestations include transient ischemic attack, stroke, and acute visual changes. As with GCA, laboratory studies are nonspecific and reveal anemia as well as elevated ESR and CRP. Angiography may demonstrate arterial stenosis or aneurysm ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_rm_f52",
"wrapId":"2",
"children":[
"Figure 52"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_rm_f52"
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_2_3_3",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"24b77d",
"children":[
"Primary treatment of TA is high-dose oral glucocorticoids (1 mg/kg/d, up to 80 mg/d) with a slow taper. Guidelines conditionally recommend adjunctive treatment with nonbiologic immunosuppressive medications (e.g., methotrexate, leflunomide, mycophenolate mofetil, azathioprine, and cyclophosphamide) to mitigate glucocorticoid exposure. For refractory disease, adding a tumor necrosis factor inhibitor is preferred over adding tocilizumab. Endovascular or reconstructive vascular procedures are sometimes required; if possible, these should be performed during periods of inactive disease. The leading cause of death is heart failure; stroke and cardiovascular disease also contribute to morbidity. The 10-year survival rate is 90%."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"0a8419",
"children":[
"Giant cell arteritis should be suspected in a patient older than 50 years with new or atypical headache, jaw claudication, or visual changes."
]
},
{
"type":"keypoint",
"hlId":"cac1f3",
"hvc":true,
"children":[
"Suspected giant cell arteritis should be treated immediately with prednisone to prevent visual loss; diagnosis can still be confirmed with temporal artery biopsy within 2 weeks after initiation of prednisone."
]
},
{
"type":"keypoint",
"hlId":"0e4f93",
"hvc":true,
"children":[
"Polymyalgia rheumatica is associated with pain and stiffness of the neck, shoulder, and pelvic girdles; it responds dramatically to moderate-dose prednisone."
]
},
{
"type":"keypoint",
"hlId":"aa58f1",
"children":[
"Takayasu arteritis occurs in younger women and causes inflammation of the aorta and other major noncranial vessels."
]
}
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_3",
"title":{
"__html":"Medium-Vessel Vasculitis"
},
"titleNode":{
"type":"section-title",
"hlId":"f38488",
"children":[
"Medium-Vessel Vasculitis"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s14_3_1",
"title":{
"__html":"Polyarteritis Nodosa"
},
"titleNode":{
"type":"section-title",
"hlId":"e7d52d",
"children":[
"Polyarteritis Nodosa"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s14_3_1_1",
"title":{
"__html":"Epidemiology and Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"c25aa6",
"children":[
"Epidemiology and Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"c1ab26",
"children":[
"Polyarteritis nodosa (PAN) is a rare systemic necrotizing vasculitis that affects medium-sized and sometimes small-sized arteries. Prevalence is approximately 31 per million but declining. Average age at onset is 50 years."
]
},
{
"type":"p",
"hlId":"041a77",
"children":[
"Historically, PAN has been strongly associated with hepatitis B virus (HBV). Because HBV prevalence has declined with the advent of the HBV vaccine and antiviral treatment, the proportion of patients with HBV-associated PAN has declined from 36% to less than 5% of all PAN cases; most contemporary cases are autoimmune. Pathophysiology is not well understood."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_3_1_2",
"title":{
"__html":"Clinical Manifestations and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c6f6f6",
"children":[
"Clinical Manifestations and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"ddf208",
"children":[
"PAN most commonly affects the skin and peripheral nervous system, as well as the gastrointestinal tract and kidneys. ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t40",
"wrapId":"3",
"children":[
"Table 40"
]
}
]
},
" lists the clinical and laboratory findings of PAN. The disease does not involve the lungs. When present, kidney involvement is renovascular rather than glomerular and often leads to hypertension. Cutaneous PAN is a variant confined to the skin. Cutaneous features of medium-vessel vasculitis include livedo reticularis ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_rm_f53",
"wrapId":"3",
"children":[
"Figure 53"
]
}
]
},
")"
]
},
" and painful deep ulcers and skin necrosis due ischemic infarction ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_rm_f54",
"wrapId":"3",
"children":[
"Figure 54"
]
}
]
},
")"
]
},
". Because of the intense inflammation of medium-sized vessels, subcutaneous nodules may be palpable."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_rm_t40",
"mk19_b_rm_f53",
"mk19_b_rm_f54"
]
},
{
"type":"p",
"hlId":"93dbeb",
"children":[
"Diagnosis is often confirmed via angiography of the mesenteric and/or renal vasculature, which demonstrates saccular microaneurysms and areas of narrowing in medium-sized vessels. The gold standard for diagnosing PAN is histologic identification of focal segmental panmural necrotizing inflammation of a medium-sized vessel, obtained on biopsy of involved, easily accessible tissue (e.g., skin or a superficial nerve)."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_3_1_3",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"96b8bc",
"children":[
"Intravenous pulse glucocorticoids and cyclophosphamide are indicated for severe organ-threatening disease; glucocorticoids and disease-modifying antirheumatic drugs are used for milder disease. HBV-associated PAN is treated with short-term glucocorticoids, antiviral medication, and plasmapheresis if necessary. The 5-year survival rate for treated PAN is 80%, and the relapse rate is 10% to 20%."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_3_2",
"title":{
"__html":"Primary Angiitis of the Central Nervous System"
},
"titleNode":{
"type":"section-title",
"hlId":"4f1955",
"children":[
"Primary Angiitis of the Central Nervous System"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s14_3_2_1",
"title":{
"__html":"Epidemiology and Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"c25aa6",
"children":[
"Epidemiology and Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"a0fdfb",
"children":[
"Primary angiitis of the central nervous system (PACNS) is a rare small- and medium-vessel vasculitis of the central nervous system; it affects the brain parenchyma, spinal cord, and leptomeninges. Incidence is 2.4 per 100,000. Median age at onset is 50 years. The three histologic presentations have a patchy distribution: granulomatous (most common), lymphocytic, and necrotizing."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_3_2_2",
"title":{
"__html":"Clinical Manifestations and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c6f6f6",
"children":[
"Clinical Manifestations and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"c745d4",
"children":[
"Patients with PACNS usually present with gradual and progressive symptoms of headache, cognitive impairment, neurologic deficits, transient ischemic attacks, and strokes. Laboratory findings are normal. Cerebrospinal fluid is abnormal but nonspecific in 80% to 90% of patients, with elevated protein, lymphocytic pleocytosis, and occasional oligoclonal bands. MRI shows nonspecific white and gray matter changes and infarcts. Magnetic resonance angiography and CT angiography have limited usefulness because of poor resolution. Cerebral angiography may demonstrate vessel “beading” (alternating dilations and stenoses) but has limited sensitivity and specificity. Brain biopsy should be performed in any patient in whom the diagnosis is seriously considered; however, the patchy distribution of findings results in a 50% false-negative rate."
]
},
{
"type":"p",
"hlId":"294d96",
"children":[
"Evaluation also focuses on ruling out other conditions, including infection, malignancy (e.g., intravascular CNS lymphoma), and reversible cerebral vasoconstriction syndrome."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_3_2_3",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"569700",
"children":[
"PACNS is treated with high-dose glucocorticoids and cyclophosphamide. Patients often have permanent disability from neurologic damage, and the recurrence rate is 27%."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_3_3",
"title":{
"__html":"Kawasaki Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"72a6f8",
"children":[
"Kawasaki Disease"
]
},
"children":[
{
"type":"p",
"hlId":"e17136",
"children":[
"Kawasaki disease is a medium-vessel vasculitis and the most common type of vasculitis in children. It presents as fever, rash, cervical lymphadenopathy, conjunctival congestion, and mucositis. Coronary vessel vasculitis is the most feared complication and may leave permanent vasculopathy if not treated promptly. Although Kawasaki disease almost never develops in adulthood, adults who had Kawasaki disease as a child may have residual coronary aneurysms that require monitoring and management. Recently a Kawasaki-like syndrome (multisystem inflammatory syndrome in children) has been identified in patients (rarely, adults) who have been infected with COVID-19."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"a93654",
"children":[
"Polyarteritis nodosa most commonly affects the skin and peripheral nervous system, as well as the gastrointestinal tract and kidneys; the gold standard for diagnosis is focal segmental panmural necrotizing inflammation of a medium-sized vessel on biopsy."
]
},
{
"type":"keypoint",
"hlId":"501ba8",
"children":[
"Patients with primary angiitis of the central nervous system usually present with gradual and progressive symptoms of headache, cognitive impairment, neurologic deficits, transient ischemic attacks, and strokes."
]
},
{
"type":"keypoint",
"hlId":"2b845a",
"children":[
"Adults who had Kawasaki disease as a child may have residual coronary aneurysms that require monitoring and management."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4",
"title":{
"__html":"Small-Vessel Vasculitis"
},
"titleNode":{
"type":"section-title",
"hlId":"7f638c",
"children":[
"Small-Vessel Vasculitis"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s14_4_1",
"title":{
"__html":"ANCA-Associated Vasculitis"
},
"titleNode":{
"type":"section-title",
"hlId":"cda251",
"children":[
"ANCA-Associated Vasculitis"
]
},
"children":[
{
"type":"p",
"hlId":"bbeb81",
"children":[
"ANCA-associated vasculitis includes three diseases characterized by the presence of ANCA ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t41",
"wrapId":"4",
"children":[
"Table 41"
]
}
]
},
")"
]
},
": granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. (ANCA-associated glomerulonephritis is discussed in MKSAP 19 Nephrology.) The presence of ANCA can be detected on serologic testing and helps to define the diseases."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_rm_t41"
]
},
{
"type":"p",
"hlId":"36bdfb",
"children":[
"The two types of vasculitis-associated ANCA are p-ANCA (perinuclear, directed against the neutrophil enzyme myeloperoxidase) and c-ANCA (cytoplasmic, directed against the neutrophil proteinase 3). Perinuclear and cytoplasmic refer to patterns of immunofluorescent staining; enzyme-linked immunosorbent assays against myeloperoxidase and proteinase 3 are used to confirm antibody positivity and in some cases to replace immunofluorescence testing."
]
},
{
"type":"p",
"hlId":"c3c9a5",
"children":[
"ANCA may play a direct role in disease propagation by activating primed endothelial cells and neutrophils, leading to vessel damage. The granulomatous inflammation in some forms of ANCA-associated vasculitis suggests a role for cell-mediated immunity. Although most cases of ANCA-associated vasculitis are idiopathic, a few are drug induced; several drugs can cause this rare reaction, including propylthiouracil and levamisole (an adulterant often found in cocaine)."
]
},
{
"type":"p",
"hlId":"1e42ec",
"children":[
"See ",
{
"type":"cross-reference",
"target":"mk19_a_np_s6_4_3",
"children":[
"MKSAP 19 Nephrology"
]
},
" for details on kidney involvement in ANCA-associated vasculitis."
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_1_1",
"title":{
"__html":"Granulomatosis With Polyangiitis"
},
"titleNode":{
"type":"section-title",
"hlId":"8f73a9",
"children":[
"Granulomatosis With Polyangiitis"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s14_4_1_1_1",
"title":{
"__html":"Epidemiology and Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"c25aa6",
"children":[
"Epidemiology and Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"8cc6be",
"children":[
"Granulomatosis with polyangiitis (GPA) is the most common ANCA-associated vasculitis, with an annual incidence of 7 to 12 per million."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_1_1_2",
"title":{
"__html":"Clinical Manifestations and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c6f6f6",
"children":[
"Clinical Manifestations and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"295e2d",
"children":[
"GPA affects the small vessels of the upper and lower airways (sinuses, lungs), kidneys, eyes (scleritis), skin, and peripheral nerves. At least 50% of patients have constitutional symptoms. More than 95% of patients are ANCA positive, with antibodies overwhelmingly (>90% of cases) directed against proteinase 3 (anti-PR3 antibodies; c-ANCA)."
]
},
{
"type":"p",
"hlId":"3a2be4",
"children":[
"GPA presents as systemic or localized disease. The systemic form is more common, involves major organs, and is associated with positivity for anti-PR3 antibodies. Patients with localized disease are more likely to be younger and female; have mainly ear, nose, and throat involvement; and are less likely to be PR-3 positive. See ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t41",
"wrapId":"5",
"children":[
"Table 41"
]
}
]
},
" for clinical features of GPA."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_b_rm_t41"
]
},
{
"type":"p",
"hlId":"07cb07",
"children":[
"Cutaneous features of GPA include petechiae or palpable purpura (both of which are nonblanching lesions; ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_rm_f55",
"wrapId":"6",
"children":[
"Figure 55"
]
}
]
},
")"
]
},
", hemorrhagic bullae, and superficial ulcers. However, any of the small-vessel vasculitides may present with these findings."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_b_rm_f55"
]
},
{
"type":"p",
"hlId":"201d7b",
"children":[
"In the setting of a classic clinical presentation and positivity for c-ANCA/anti-PR3 antibodies, diagnosis of GPA is straightforward. However, because of significant risks of treatment, biopsy of involved tissue is usually recommended if possible. Histopathology of most tissues demonstrates pauci-immune necrotizing granulomatous vasculitis; pauci-immune necrotizing glomerulonephritis without granulomas is seen on kidney biopsy."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_1_1_3",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"472685",
"children":[
"To induce remission in severe organ-threatening or life-threatening disease, treatment of GPA consists of high-dose oral glucocorticoids or intravenous glucocorticoids plus rituximab (preferred) or cyclophosphamide; selected patients may benefit from plasma exchange. Once remission is achieved, patients should receive maintenance therapy consisting of rituximab, methotrexate, or azathioprine; rituximab appears to be most effective for preventing relapse and is preferred. It remains unclear whether suppressive maintenance therapy can be fully withdrawn because relapse in GPA is common (historically, >50% after initial remission). Glucocorticoids alone are insufficient to control GPA. Patients with limited presentations of GPA (such as arthropathy or upper airway disease) without organ-threatening disease can sometimes be treated with glucocorticoids plus methotrexate; such patients should be carefully monitored for treatment failure or development of kidney or other organ-threatening disease, necessitating a more aggressive regimen. With use of these approaches, GPA mortality has declined from 90% to around 10%. Kidney failure and infection remain the main causes of death."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_1_2",
"title":{
"__html":"Microscopic Polyangiitis"
},
"titleNode":{
"type":"section-title",
"hlId":"ddfac5",
"children":[
"Microscopic Polyangiitis"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s14_4_1_2_1",
"title":{
"__html":"Epidemiology and Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"c25aa6",
"children":[
"Epidemiology and Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"022386",
"children":[
"The annual incidence of microscopic polyangiitis (MPA) is estimated at 2.7 per million in Europe and lower elsewhere. Average age at onset is 50 to 60 years, with a predilection for men over women (1.8:1). Compared with GPA, ANCAs are less prevalent (50%-75%) and usually directed against myeloperoxidase."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_1_2_2",
"title":{
"__html":"Clinical Manifestations and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c6f6f6",
"children":[
"Clinical Manifestations and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"4ff336",
"children":[
"Like GPA, MPA characteristically affects the lungs and kidneys, along with other organ systems. In contrast to GPA, MPA tends to spare the upper airways, and lung involvement is not granulomatous on biopsy. See ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t41",
"wrapId":"7",
"children":[
"Table 41"
]
}
]
},
" for the clinical features of MPA. Diagnosis is suspected on the basis of typical clinical findings and positivity for myeloperoxidase ANCA, although negativity for ANCA does not rule out the diagnosis. The diagnostic gold standard is a biopsy specimen demonstrating necrotizing pauci-immune vasculitis of small vessels in any affected tissue or pauci-immune necrotizing crescentic glomerulonephritis in the kidney. Absence of granulomas distinguishes MPA from GPA."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_b_rm_t41"
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_1_2_3",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"1c219a",
"children":[
"Treatment of MPA is similar to that of GPA."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_1_3",
"title":{
"__html":"Eosinophilic Granulomatosis With Polyangiitis"
},
"titleNode":{
"type":"section-title",
"hlId":"f02d3c",
"children":[
"Eosinophilic Granulomatosis With Polyangiitis"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s14_4_1_3_1",
"title":{
"__html":"Epidemiology and Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"c25aa6",
"children":[
"Epidemiology and Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"ca4bf7",
"children":[
"Eosinophilic granulomatosis with polyangiitis (EGPA) is the rarest ANCA-associated vasculitis, with an annual incidence of 0.11 to 2.66 per million. Eosinophil infiltration, activation, and degranulation participate in disease pathogenesis."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_1_3_2",
"title":{
"__html":"Clinical Manifestations and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c6f6f6",
"children":[
"Clinical Manifestations and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"b43065",
"children":[
"The typical patient with EGPA has a prodromal history of difficult-to-treat asthma (96%-100%), rhinitis, and/or atopy. A phase with increased peripheral and tissue eosinophilia follows, with migratory pulmonary infiltrates and, less commonly, endomyocardial infiltration and gastrointestinal disease. The subsequent acute vasculitic phase includes mononeuritis multiplex or peripheral sensorimotor neuropathy (70%), kidney involvement (25%), and skin involvement (60%). The vasculitis phase is often associated with improvement of asthma. See ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t41",
"wrapId":"8",
"children":[
"Table 41"
]
}
]
},
" for the clinical features of EGPA."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_b_rm_t41"
]
},
{
"type":"p",
"hlId":"406afa",
"children":[
"Laboratory findings show peripheral eosinophilia of more than 10%, or more than 1500/μL (1.5 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L). Only about 40% to 60% of patients have a positive ANCA result, mostly directed against myeloperoxidase."
]
},
{
"type":"p",
"hlId":"ae2a5f",
"children":[
"Diagnosis is based on typical clinical findings, eosinophilia, and biopsy specimens demonstrating fibrinoid necrosis and eosinophilic infiltration of vessel walls, as well as extravascular granuloma formation."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_1_3_3",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"e2a7a4",
"children":[
"In EGPA, glucocorticoids alone may be sufficient for mild disease without major organ involvement. With kidney, gastrointestinal, cardiac, or neurologic involvement, cyclophosphamide had been indicated in the past. However, mepolizumab, a monoclonal antibody that binds interleukin-5, has been FDA approved for EGPA and has a more favorable safety profile than cyclophosphamide."
]
},
{
"type":"p",
"hlId":"c38eb9",
"children":[
"Mortality for EGPA is the lowest among all forms of ANCA-associated vasculitis. The 5-year survival is 97%, and the relapse rate is 28%. If not treated early, neuropathy may become permanent."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"13bece",
"children":[
"Granulomatosis with polyangiitis affects the upper and lower airways, kidneys, eyes, skin, and peripheral nerves; induction of remission in severe organ-threatening or life-threatening disease consists of high-dose glucocorticoids rituximab (preferred) or cyclophosphamide."
]
},
{
"type":"keypoint",
"hlId":"b7be5e",
"children":[
"Microscopic polyangiitis characteristically affects the lungs and kidneys; treatment is the same as that for granulomatosis with polyangiitis."
]
},
{
"type":"keypoint",
"hlId":"279489",
"children":[
"Eosinophilic granulomatosis with polyangiitis is associated with asthma, rhinitis, sinusitis, atopy, peripheral and tissue eosinophilia, migratory pulmonary infiltrates, and mononeuritis multiplex or peripheral sensorimotor neuropathy; treatment consists of glucocorticoids for mild disease, with mepolizumab or cyclophosphamide added for more severe disease."
]
}
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_2",
"title":{
"__html":"Immune Complex–Mediated Vasculitis"
},
"titleNode":{
"type":"section-title",
"hlId":"44c112",
"children":[
"Immune Complex–Mediated Vasculitis"
]
},
"children":[
{
"type":"p",
"hlId":"e91f48",
"children":[
"Immune complexes develop from cross-linking of multiple antigens and antibodies. Immune complexes can deposit in small vessels, leading to complement and neutrophil activation, with consequent inflammation and tissue damage. Although any tissue or organ may be affected, the classic finding is invariably in the skin. Inflammation and erythrocyte extravasation from damaged vessels result in nonblanching palpable purpura, usually in dependent areas ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_rm_f56",
"wrapId":"9",
"children":[
"Figure 56"
]
}
]
},
")"
]
},
". The various immune complex–mediated vasculitides are distinguished by the antigen that drives them, the class of antibody generated, and differences in clinical presentations."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_b_rm_f56"
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_2_1",
"title":{
"__html":"Cryoglobulinemic Vasculitis"
},
"titleNode":{
"type":"section-title",
"hlId":"2a58e2",
"children":[
"Cryoglobulinemic Vasculitis"
]
},
"children":[
{
"type":"p",
"hlId":"d3f0e6",
"children":[
"Cryoglobulins cause an immune complex–mediated small-vessel vasculitis primarily affecting the skin, peripheral nervous system, and kidneys. CNS involvement may rarely occur. There are three types of cryoglobulins. Type I occurs as a consequence of malignant monoclonal gammopathies and B-cell lymphoma. Types II and III are polyclonal and “mixed” in nature. Each is formed from the interaction of antigen-targeted antibodies with rheumatoid factor; type II cryoglobulins include a monoclonal IgM rheumatoid factor, whereas in type III cryoglobulins the rheumatoid factor is a polyclonal IgM. The ability of rheumatoid factor to directly bind other antibodies facilitates the formation of immune complexes even in the absence of persistent antigen. In addition to their ability to form immune complexes, all cryoglobulins demonstrate the unique feature of precipitating in the cold. See ",
{
"type":"cross-reference",
"target":"mk19_b_hm_s3_7",
"children":[
"MKSAP 19 Hematology"
]
},
" for details on type I cryoglobulins. See ",
{
"type":"cross-reference",
"target":"mk19_b_hm_s4_3_2_1_2",
"children":[
"MKSAP 19 Hematology"
]
},
" for the differentiation of cryoglobulinemia from cold agglutinin disease."
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_2_1_1",
"title":{
"__html":"Epidemiology and Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"c25aa6",
"children":[
"Epidemiology and Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"842b72",
"children":[
"Mixed cryoglobulinemia, which accounts for 75% to 90% of all cases of cryoglobulinemic vasculitis, is rare, with an estimated prevalence of 1 in 100,000. About two thirds of mixed cryoglobulinemia (type II and type III) cases are related to hepatitis C virus infection. Autoimmune diseases, such as systemic lupus erythematosus and Sjögren syndrome, more typically cause type III cryoglobulinemia."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_2_1_2",
"title":{
"__html":"Clinical Manifestations and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c6f6f6",
"children":[
"Clinical Manifestations and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"7e387e",
"children":[
"Cutaneous symptoms (palpable purpura, digital ischemia, ulcers, necrosis, and livedo reticularis) are seen in about 90% of patients. Other common manifestations include peripheral neuropathy, arthralgia without arthritis, and glomerulonephritis (usually membranoproliferative). Pulmonary and/or gastrointestinal involvement is rare. Testing for cryoglobulins requires that a sample of blood be maintained at 37.0 °C (98.6 °F) until clotting is complete to avoid incorporation of the cryoglobulins into the clot. In addition to detection of cryoglobulins, laboratory abnormalities frequently include depressed C4 complement and low CH50 levels. Patients with type II and type III cryoglobulinemia have positivity for rheumatoid factor. A false-negative cryoglobulin result is not unusual given the complexity of cryoglobulin testing."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_2_1_3",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"056f9a",
"children":[
"Treatment of cryoglobulinemia requires first addressing the cause of the disease, such as instituting antiviral therapy for hepatitis C virus–related cryoglobulinemia. When the consequences of the cryoglobulinemia are severe (e.g., glomerulonephritis, ulcerating cutaneous lesions, digital gangrene), the vasculitis itself must also be treated. Glucocorticoids and rituximab in combination are the standard first-line therapy."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_2_2",
"title":{
"__html":"IgA Vasculitis"
},
"titleNode":{
"type":"section-title",
"hlId":"ccedb4",
"children":[
"IgA Vasculitis"
]
},
"children":[
{
"type":"p",
"hlId":"cd24ee",
"children":[
"See ",
{
"type":"cross-reference",
"target":"mk19_a_np_s6_4_4",
"children":[
"MKSAP 19 Nephrology"
]
},
" for information on IgA nephropathy and on kidney involvement in IgA vasculitis."
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_2_2_1",
"title":{
"__html":"Epidemiology and Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"c25aa6",
"children":[
"Epidemiology and Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"03aba1",
"children":[
"IgA vasculitis (Henoch-Schönlein purpura) is a common vasculitis of childhood that rarely occurs in adults. Estimated annual incidence in adults is 14 per million. Onset is usually preceded by upper respiratory tract infection, often with streptococcal bacteria."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_2_2_2",
"title":{
"__html":"Clinical Manifestations and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c6f6f6",
"children":[
"Clinical Manifestations and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"7629ce",
"children":[
"Patients with IgA vasculitis typically present with palpable purpura in dependent areas. Other common findings include abdominal pain or gastrointestinal bleeding (50%), arthritis and arthralgia (60%), and glomerulonephritis. Although progressive renal damage may occur, 90% of adults with kidney involvement fully recover."
]
},
{
"type":"p",
"hlId":"85fc42",
"children":[
"There are no specific laboratory tests for diagnosis. Diagnosis is confirmed by demonstrating IgA tissue deposition, generally in the skin, by immunofluorescent microscopy. Skin biopsy demonstrates leukocytoclastic vasculitis with heavy deposits of IgA and complement on immunofluorescent staining. Although rarely necessary, renal histology shows IgA deposition within the mesangium."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_2_2_3",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"4d226d",
"children":[
"Although IgA vasculitis in children tends to be self-limited, adults are more likely to develop persistent nephropathy and may require glucocorticoids. Despite lack of evidence, some patients may require additional immunosuppression (cyclophosphamide or rituximab)."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_2_3",
"title":{
"__html":"Hypersensitivity Vasculitis"
},
"titleNode":{
"type":"section-title",
"hlId":"a84c8a",
"children":[
"Hypersensitivity Vasculitis"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s14_4_2_3_1",
"title":{
"__html":"Epidemiology and Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"c25aa6",
"children":[
"Epidemiology and Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"0a42e2",
"children":[
"Hypersensitivity vasculitis is a small-vessel vasculitis mediated by immune complex deposition confined to the skin. It may be triggered by an antigen, such as a drug or infection; in 50% of cases, the antigen is unknown. Men and women and people of all ages are affected."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_2_3_2",
"title":{
"__html":"Clinical Manifestations and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c6f6f6",
"children":[
"Clinical Manifestations and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"0aab08",
"children":[
"The most common presentation of hypersensitivity vasculitis is palpable purpura in dependent regions, often developing 7 to 10 days after exposure to a triggering antigen; lesions appear in “crops” and resolve over a few weeks after the antigen is removed. Internal organs are unaffected. Skin biopsy with immunofluorescence demonstrates leukocytoclastic vasculitis without heavy IgA deposits. Evaluation should be guided by clinical signs and symptoms and may require only a complete blood count, basic chemistries, and urinalysis."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_4_2_3_3",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"ebec54",
"children":[
"Removal of the antigen (if identified) and supportive care are usually sufficient. Resolution within a month is the rule. If symptoms persist or recur, anti-inflammatory agents, topical or low-dose systemic glucocorticoids, colchicine, or dapsone may be helpful."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"69e550",
"children":[
"Mixed cryoglobulinemia is associated with cutaneous symptoms, peripheral neuropathy, arthralgia without arthritis, and glomerulonephritis, with two thirds of cases related to hepatitis C virus infection."
]
},
{
"type":"keypoint",
"hlId":"c91a80",
"children":[
"IgA vasculitis (Henoch-Schönlein purpura) is characterized by palpable purpura and abdominal pain or gastrointestinal bleeding and occurs mainly in children."
]
},
{
"type":"keypoint",
"hlId":"c7e964",
"children":[
"The most common presentation of hypersensitivity vasculitis is palpable purpura, developing 7 to 10 days after exposure to a triggering antigen."
]
}
]
}
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s14_5",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Cacoub P, Comarmond C, Domont F, et al. Cryoglobulinemia vasculitis. Am J Med. 2015;128:950-5. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/25837517",
"target":"_blank"
},
"children":[
"PMID: 25837517"
]
},
" doi:10.1016/j.amjmed.2015.02.017"
]
},
{
"type":"reference",
"children":[
"Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73:1366-1383. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34235894",
"target":"_blank"
},
"children":[
"PMID: 34235894"
]
}
]
},
{
"type":"reference",
"children":[
"Chung SA, Gorelik M, Langford CA, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of polyarteritis nodosa. Arthritis Care Res (Hoboken). 2021;73:1061-1070. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34235889",
"target":"_blank"
},
"children":[
"PMID: 34235889"
]
}
]
},
{
"type":"reference",
"children":[
"Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;77:636-643. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29358285",
"target":"_blank"
},
"children":[
"PMID: 29358285"
]
},
" doi:10.1136/annrheumdis-2017-212649"
]
},
{
"type":"reference",
"children":[
"Demirkesen C. Approach to cutaneous vasculitides with special emphasis on small vessel vasculitis: histopathology and direct immunofluorescence. Curr Opin Rheumatol. 2017;29:39-44. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27787337",
"target":"_blank"
},
"children":[
"PMID: 27787337"
]
}
]
},
{
"type":"reference",
"children":[
"Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19-30. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31270110",
"target":"_blank"
},
"children":[
"PMID: 31270110"
]
},
" doi:10.1136/annrheumdis-2019-215672"
]
},
{
"type":"reference",
"children":[
"Jones RB, Hiemstra TF, Ballarin J, et al; European Vasculitis Study Group (EUVAS). Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis. 2019;78:399-405. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30612116",
"target":"_blank"
},
"children":[
"PMID: 30612116"
]
},
" doi:10.1136/annrheumdis-2018-214245"
]
},
{
"type":"reference",
"children":[
"Mandal J, Chung SA. Primary angiitis of the central nervous system. Rheum Dis Clin North Am. 2017;43:503-518. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29061238",
"target":"_blank"
},
"children":[
"PMID: 29061238"
]
},
" doi:10.1016/j.rdc.2017.06.001"
]
},
{
"type":"reference",
"children":[
"Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021;73:1349-1365. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34235884",
"target":"_blank"
},
"children":[
"PMID: 34235884"
]
}
]
},
{
"type":"reference",
"children":[
"Terrier B, Pagnoux C, Perrodeau É, et al; French Vasculitis Study Group. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis. 2018;77:1150-1156. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29724729",
"target":"_blank"
},
"children":[
"PMID: 29724729"
]
},
" doi:10.1136/annrheumdis-2017-212768"
]
},
{
"type":"reference",
"children":[
"Wechsler ME, Akuthota P, Jayne D, et al; EGPA Mepolizumab Study Team. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376:1921-1932. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28514601",
"target":"_blank"
},
"children":[
"PMID: 28514601"
]
},
" doi:10.1056/NEJMoa1702079"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_rm_t38":{
"id":"mk19_b_rm_t38",
"number":38,
"bookId":"rm",
"title":{
"__html":"Causes of Secondary Vasculitis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"bd6542",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 38. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t38"
}
]
},
"Causes of Secondary Vasculitis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ba25cf",
"class":"col hd l",
"children":[
"Medications"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b1c27f",
"class":"cell txt l",
"children":[
"Common causes: antimicrobial agents (e.g., minocycline, sulfadiazine); antithyroid agents (propylthiouracil [80%-90%], methimazole, carbimazole, benzylthiouracil [10%-20%; not available in the United States]); cardiovascular drugs (hydralazine); tumor necrosis factor inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"4d9592",
"class":"cell txt l",
"children":[
"Rare causes: vaccines; antiepileptic agents; antiarrhythmic agents; diuretics; anticoagulants; antineoplastic agents; hematopoietic growth factors; NSAIDs; psychotropic drugs; sympathomimetic agents; allopurinol; interferon alfa; levamisole (associated with cocaine)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2c194f",
"class":"col hd l",
"children":[
"Infections"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"31cd4c",
"class":"cell txt l",
"children":[
"Hepatitis A, B, and C viruses; HIV; bacterial endocarditis; parvovirus B19"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4d0302",
"class":"col hd l",
"children":[
"Neoplasms"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e0d866",
"class":"cell txt l",
"children":[
"Hairy cell leukemia (associated with polyarteritis nodosa); other hematologic and solid malignancies"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9f4f09",
"class":"col hd l",
"children":[
"Autoimmune Diseases"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"52543c",
"class":"cell txt l",
"children":[
"Systemic lupus erythematosus; rheumatoid arthritis; Sjögren syndrome; inflammatory myopathies; systemic sclerosis; relapsing polychondritis; inflammatory bowel disease; primary biliary cirrhosis"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_rm_t39":{
"id":"mk19_b_rm_t39",
"number":39,
"bookId":"rm",
"title":{
"__html":"Differential Diagnosis (Including Mimics) of Vasculitis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"08c434",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 39. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t39"
}
]
},
"Differential Diagnosis (Including Mimics) of Vasculitis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e7067a",
"class":"col hd l",
"children":[
"Disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e0541a",
"class":"cell txt l",
"children":[
"Infection (sepsis, endocarditis, hepatitis)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"48d46e",
"class":"cell txt l",
"children":[
"Rash and/or musculoskeletal symptoms can occur."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5f9b3e",
"class":"cell txt l",
"children":[
"Drug toxicity/poisoning"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c06f82",
"class":"cell txt l",
"children":[
"Cocaine, amphetamines, ephedra alkaloids, and phenylpropanolamine may produce vasospasm, resulting in ischemia."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"230aaf",
"class":"cell txt l",
"children":[
"Coagulopathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7b7d5a",
"class":"cell txt l",
"children":[
"Thrombotic diseases (disseminated intravascular coagulation; antiphospholipid syndrome; thrombotic thrombocytopenic purpura) can produce ischemic symptoms."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"986a4f",
"class":"cell txt l",
"children":[
"Malignancy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1942b0",
"class":"cell txt l",
"children":[
"Paraneoplastic vasculitis is rare. Any organ system may be affected, but the skin and nervous system are the most common. Vasculitic symptoms may precede, occur simultaneously with, or follow diagnosis of cancer. Lymphoma occasionally may involve the blood vessels and mimic vasculitis. Consider malignancy in patients with incomplete or no response to therapy for idiopathic vasculitis."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"57b406",
"class":"cell txt l",
"children":[
"Atrial myxoma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"edda2c",
"class":"cell txt l",
"children":[
"Classic triad of symptoms is embolism, pulmonary congestion or heart failure, and constitutional symptoms (fatigue; weight loss; fever). Skin lesions can be identical to those seen in leukocytoclastic vasculitis."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"22e8f4",
"class":"cell txt l",
"children":[
"Cholesterol emboli"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5e38eb",
"class":"cell txt l",
"children":[
"Typically seen in patients with severe atherosclerosis. Embolization may occur after abdominal trauma, aortic surgery, or angiography. May also occur after heparin, warfarin, or thrombolytic therapy. Patients may have livedo reticularis, petechiae and purpuric lesions, and localized skin necrosis."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_rm_t40":{
"id":"mk19_b_rm_t40",
"number":40,
"bookId":"rm",
"title":{
"__html":"Clinical Features of Polyarteritis Nodosa"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"dd2360",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 40. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t40"
}
]
},
"Clinical Features of Polyarteritis Nodosa"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93da7a",
"class":"col hd l",
"children":[
"Organ System"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd2968",
"class":"col hd l",
"children":[
"Symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7cf395",
"class":"col hd l",
"children":[
"Frequency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e6ff45",
"class":"cell txt l",
"children":[
"Constitutional"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"633762",
"class":"cell txt l",
"children":[
"Fever; malaise; weight loss"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ae4ae6",
"class":"cell txt l",
"children":[
"65%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26aeab",
"class":"cell txt l",
"children":[
"—"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9b3d4d",
"class":"cell txt l",
"children":[
"Musculoskeletal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d9d1ec",
"class":"cell txt l",
"children":[
"Arthralgia; myalgia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4b1251",
"class":"cell txt l",
"children":[
"55%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26aeab",
"class":"cell txt l",
"children":[
"—"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"931356",
"class":"cell txt l",
"children":[
"Skin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d4efe9",
"class":"cell txt l",
"children":[
"Purpura; nodules; necrotic ulcers"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cff3c3",
"class":"cell txt l",
"children":[
"50%-60%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26aeab",
"class":"cell txt l",
"children":[
"—"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2bd728",
"class":"cell txt l",
"children":[
"Neurologic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fc96f0",
"class":"cell txt l",
"children":[
"Mononeuritis multiplex; peripheral neuropathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2dd30b",
"class":"cell txt l",
"children":[
"79%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26e432",
"class":"cell txt l",
"children":[
"Wrist drop; foot drop"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4ff2bb",
"class":"cell txt l",
"children":[
"Kidney"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cc47ab",
"class":"cell txt l",
"children":[
"Hypertension; hematuria; proteinuria"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8a6b53",
"class":"cell txt l",
"children":[
"40%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"970619",
"class":"cell txt l",
"children":[
"Renal artery microaneurysms with tissue infarct/hematoma; no glomerulonephritis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef024b",
"class":"cell txt l",
"children":[
"Gastrointestinal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"54ed12",
"class":"cell txt l",
"children":[
"Mesenteric ischemia; intestinal perforation; pancreatitis; cholecystitis; appendicitis; gastrointestinal bleeding"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b89109",
"class":"cell txt l",
"children":[
"38%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4c885b",
"class":"cell txt l",
"children":[
"One third of gastrointestinal cases manifest as acute abdomen"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6caee8",
"class":"cell txt l",
"children":[
"Testicular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b03ac",
"class":"cell txt l",
"children":[
"Orchitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e0db9",
"class":"cell txt l",
"children":[
"17%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"20f714",
"class":"cell txt l",
"children":[
"Usually unilateral, due to testicular artery involvement"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6311ae",
"class":"cell txt l",
"children":[
"Other"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ae584",
"class":"cell txt l",
"children":[
"Sensorineural hearing loss"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d6b98a",
"class":"cell txt l",
"children":[
"Case reports"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"09a83d",
"class":"cell txt l",
"children":[
"Bilateral; symmetric; sudden onset; rapidly progressive"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e684d8",
"class":"cell txt l",
"children":[
"Laboratory"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"04b4a2",
"class":"cell txt l",
"children":[
"Elevated erythrocyte sedimentation rate in 82%; elevated C-reactive protein; leukocytosis; anemia; thrombocytosis; increased liver chemistry test result in 33%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26aeab",
"class":"cell txt l",
"children":[
"—"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26aeab",
"class":"cell txt l",
"children":[
"—"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_rm_t41":{
"id":"mk19_b_rm_t41",
"number":41,
"bookId":"rm",
"title":{
"__html":"Clinical Features of ANCA-Associated Vasculitis Diseases"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"116ec3",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 41. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t41"
}
]
},
"Clinical Features of ANCA-Associated Vasculitis Diseases"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"col hd l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f73a9",
"class":"col hd l",
"children":[
"Granulomatosis With Polyangiitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ddfac5",
"class":"col hd l",
"children":[
"Microscopic Polyangiitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f02d3c",
"class":"col hd l",
"children":[
"Eosinophilic Granulomatosis With Polyangiitis"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8340e6",
"class":"cell txt l",
"children":[
"ANCA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"869a48",
"class":"cell txt l",
"children":[
"c-ANCA (antiproteinase-3 antibodies) (>95%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"94a871",
"class":"cell txt l",
"children":[
"p-ANCA (antimyeloperoxidase antibodies) (50%-75%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ad33ef",
"class":"cell txt l",
"children":[
"p-ANCA (antimyeloperoxidase antibodies) (~50%)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8220b2",
"class":"cell txt l",
"children":[
"Vascular histology"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b11695",
"class":"cell txt l",
"children":[
"Pauci-immune necrotizing granulomatous vasculitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"820814",
"class":"cell txt l",
"children":[
"Pauci-immune nongranulomatous necrotizing vasculitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90a35b",
"class":"cell txt l",
"children":[
"Pauci-immune necrotizing granulomatous vasculitis with eosinophilic infiltration of vessel walls and tissues; extravascular granulomas"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d521f",
"class":"cell txt l",
"children":[
"Cardiac"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de3311",
"class":"cell txt l",
"children":[
"Pericarditis; myocarditis; conduction disorder (<10%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26aeab",
"class":"cell txt l",
"children":[
"—"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"71dca5",
"class":"cell txt l",
"children":[
"Pericarditis; endomyocarditis; conduction disorder; heart failure (27%-47%)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1c59af",
"class":"cell txt l",
"children":[
"Ears/nose/throat"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"86bab9",
"class":"cell txt l",
"children":[
"Crusting; rhinorrhea; sinusitis; otitis media; chondritis of ears and nose with saddle nose deformity; septal perforation (70%-100%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c1b518",
"class":"cell txt l",
"children":[
"Sinusitis; sensorineural hearing loss (9%-30%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de5c42",
"class":"cell txt l",
"children":[
"Nasal polyps; rhinitis; sinusitis (prodromal)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef024b",
"class":"cell txt l",
"children":[
"Gastrointestinal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2e7279",
"class":"cell txt l",
"children":[
"Ulceration; perforation (5%-11%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e617f",
"class":"cell txt l",
"children":[
"Abdominal pain; bleeding (30%-58%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3de163",
"class":"cell txt l",
"children":[
"Abdominal pain; bleeding"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4ff2bb",
"class":"cell txt l",
"children":[
"Kidney"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d5b9f5",
"class":"cell txt l",
"children":[
"Pauci-immune necrotizing glomerulonephritis (40%-100%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"654af6",
"class":"cell txt l",
"children":[
"Pauci-immune necrotizing glomerulonephritis (80%-100%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f017db",
"class":"cell txt l",
"children":[
"Pauci-immune necrotizing glomerulonephritis (25%)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"efb2b0",
"class":"cell txt l",
"children":[
"Lung"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8cb263",
"class":"cell txt l",
"children":[
"Alveolar hemorrhage; nodules; tracheal/subglottic stenosis (50%-90%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b9348a",
"class":"cell txt l",
"children":[
"Alveolar hemorrhage; pulmonary infiltrates; pulmonary fibrosis (25%-55%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d7469b",
"class":"cell txt l",
"children":[
"Asthma (prodromal, >90%); nodular opacities; infiltrates (25%-86%)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4707c6",
"class":"cell txt l",
"children":[
"Ocular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"904d0e",
"class":"cell txt l",
"children":[
"Scleritis; episcleritis; retinal vasculitis; retro-orbital pseudotumor; dacryoadenitis (14%-60%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26aeab",
"class":"cell txt l",
"children":[
"—"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26aeab",
"class":"cell txt l",
"children":[
"—"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"931356",
"class":"cell txt l",
"children":[
"Skin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7a21aa",
"class":"cell txt l",
"children":[
"Petechiae/purpura; painful skin lesions; maculopapular rash; livedo reticularis; ulcers"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7a21aa",
"class":"cell txt l",
"children":[
"Petechiae/purpura; painful skin lesions; maculopapular rash; livedo reticularis; ulcers"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7a21aa",
"class":"cell txt l",
"children":[
"Petechiae/purpura; painful skin lesions; maculopapular rash; livedo reticularis; ulcers"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2bd728",
"class":"cell txt l",
"children":[
"Neurologic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fc984d",
"class":"cell txt l",
"children":[
"Mononeuritis multiplex, sensorimotor peripheral neuropathy (33%)"
]
},
" ",
{
"type":"p",
"hlId":"7c24cb",
"class":"cell txt l",
"children":[
"Central nervous system involvement (pachymeningitis) (<5%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"77008a",
"class":"cell txt l",
"children":[
"Distal symmetric polyneuropathy; mononeuritis multiplex (37%-72%)"
]
},
" ",
{
"type":"p",
"hlId":"f11788",
"class":"cell txt l",
"children":[
"Central nervous system pachymeningitis; cerebral hemorrhage; infarcts (<20%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e7874b",
"class":"cell txt l",
"children":[
"Sensorimotor peripheral neuropathy, mononeuritis multiplex (70%)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
}
}
}